Autism Spectrum DisorderPhase 2CASCADENCT04520685
CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr
A Phase 2 study testing Oral cannabidiol 100mg/mL in people with Autism Spectrum Disorder, run by University of Colorado, Denver at 1 site in United States.
Trial summary
This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study. Read more about this study
- Who is it for?
- Ages 5 to 17 years
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- Oral cannabidiol 100mg/mL
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 86 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Dec 2021to 31 Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Male or female children and adolescents aged 5-17 years, inclusive, at the time of screening.
- Judged by the investigator to be in good health at screening based upon the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results.
- Patients must have a previous documented diagnosis of ASD by a medical or psychological professional.
- Patients must be assessed by the Investigator as being moderately to severely impacted due to ASD
- Patients who are taking psychotropic medication(s) should be on a stable regimen of no more than 2 medications for at least 4 weeks preceding study Screening and must maintain that regimen throughout the study. Psychotropic medications include (but are not limited to) antipsychotics, antidepressants, mood stabilizers, anxiolytics, and ADHD medications.
- Patients with a history of seizure disorders must currently be receiving treatment with a stable regimen of one or two AEDs, or must be seizure-free for 1 year if not currently receiving AEDs.
Show all 15Show fewer
- Patients with seizures should be on a stable regimen for the 3 months preceding study enrollment of no more than 2 of the permitted anti-epileptic drugs (AEDs). Patients must remain on a stable AED dose throughout the study.
- If patients are receiving non-pharmacological educational, behavioral, and/or dietary interventions or therapies, they must be stable and have been doing so for 2 months prior to screening. Changes with school breaks are expected and do not apply.
- Patients must have a BMI of between 12-32 kg/m2 (inclusive).
- Females of childbearing potential and must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at all designated visits.
- Patients/caregivers agree to abide by all study restrictions and comply with all study procedures.
- Parents/caregivers must be able to read and respond to questions and questionnaires in English.
- Patients/caregivers must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
- Parents/caregiver(s) must provide written consent to assist in study drug administration.
- In the Investigator's opinion, patients/caregivers are reliable and willing and able to comply with all protocol requirements and procedures (including scheduled visits and confinement periods).
Who cannot join
- Adolescent females who are pregnant, nursing, or planning a pregnancy. Females of childbearing potential and male patients with a partner of childbearing potential who are unwilling or unable to use standard acceptable methods of contraception (including abstinence, hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, or intrauterine device) for the duration of the study and for 1 month after the last dose of study medication.
- History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to CBD (Epidiolex) or its ingredients.
- Exposure to any investigational drug or device < 30 days prior to screening, or plans to take another investigational drug at any time during the study.
- Use of any THC or CBD-containing product within 4 weeks of Screening Visit, planned use during the study, or positive THC urine test at screening.
- Patient is using the following medications: clobazam (Onfi, Frisium), felbamate (Felbatol), vigabatrin (Sabril), or everolimus (Afinitor).
- Plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
Show all 11Show fewer
- Patient has ALT, AST, total bilirubin, or creatinine levels ≥ 2 times the ULN, alkaline phosphatase levels ≥ 3 times the ULN, or Hct <1.2 times the LLN as determined from screening safety laboratories.
- Severe or unstable symptoms of ASD that may interfere with the study outcome evaluations and interpretation of results.
- Suffering from acute or progressive neurological disease, psychosis, schizophrenia or any psychiatric disorder or severe psychiatric abnormalities that are likely to require changes in drug therapy or interfere with the objectives of the study or the ability to adhere to protocol requirements.
- Has suspected or confirmed cardiovascular disease.
- History of treatment for, or evidence of, drug or alcohol abuse within the past year.
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Hospital Colorado
Aurora, Colorado, 80045
About this study
Official title: CAnnabidiol Study in Children With Autism Spectrum DisordEr (CASCADE): A Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Cannabidiol in Children and Adolescents With Autism
This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.
Read the detailed description
Autism spectrum disorder (ASD) is a relatively common neurodevelopmental disorder manifest by social communication deficits and restricted and repetitive interests. Individuals with ASD often have behavioral issues and psychiatric comorbidities which can be very hard to manage. Currently, there are only two FDA approved medications (aripiprazole and risperidone) for the treatment of irritability in ASD. Both medications have the potential for side effects and are not tolerated in all children with ASD. Anecdotal and some preliminary studies suggest that cannabidiol (CBD), a non-psychoactive cannabinoid in the marijuana plant, may lead to improvements in symptoms of ASD including irritability, aggressive behaviors, and anxiety.
In this study the investigators will test whether CBD leads to differences in behaviors commonly associated with ASD. The main behavioral problems investigators will study are irritability and aggressive behavior. This study will also measure changes in other behaviors seen in ASD such as anxiety, social interaction difficulties, repetitive behaviors, attentional problems, hyperactivity, repetitive behaviors, and quality of life. Study investigators will also test whether there are any important side effects of CBD in children and adolescents with ASD.
- Conditions
- Autism Spectrum Disorder
- Being tested
- Oral cannabidiol 100mg/mL, Placebo
- Keywords
- CBD, cannabidiol, ASD, autism spectrum disorder, autism
- Medical subject headings
- Autism Spectrum Disorder, Autistic Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral cannabidiol 100mg/mLDrug
In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
PlaceboDrug
In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: 12 weeks of study drug then 15 weeks of placebo | Experimental | Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks. Receives: Drug: Oral cannabidiol 100mg/mL; Drug: Placebo |
| Arm 3: 15 weeks of placebo then 12 weeks of study drug | Experimental | Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks. Receives: Drug: Oral cannabidiol 100mg/mL; Drug: Placebo |
| Arm 3: 27 weeks of study drug | Experimental | Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment. Receives: Drug: Oral cannabidiol 100mg/mL |
What is being measured
The primary outcome is the main question the study is designed to answer.
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Irritability subscale range is from 0 to 45.
Measured: Baseline to Week 12
Secondary outcomes (23)
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Lethargy/Social Withdrawal subscale
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Lethargy/Social Withdrawal subscale range is from 0 to 48.
Measured: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Stereotypic Behavior subscale
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Stereotypic Behavior subscale range is from 0 to 21.
Measured: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Inappropriate Speech subscale
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Inappropriate Speech subscale range is from 0 to 12.
Measured: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Hyperactivity/Noncompliance subscale
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Hyperactivity/Noncompliance subscale range is from 0 to 48.
Measured: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): Total Score
The Anxiety, Depression, and Mood Scale (ADAMS) is a 28-item parent-report scale designed for individuals with disabilities to measure domains of anxiety (range 0 - 21), depression (range 0 - 21), hyperactivity (range 0 - 15), social avoidance (range 0 - 21), and obsessive/compulsive behavior (range 0 - 9). The total score is the sum of all items (range 0 - 87). Items are rated on a scale of "not a problem" (0) to "severe problem" (3).
Measured: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): General Anxiety subscale
The Anxiety, Depression, and Mood Scale (ADAMS) is a 28-item parent-report scale designed for individuals with disabilities to measure domains of anxiety (range 0 - 21), depression (range 0 - 21), hyperactivity (range 0 - 15), social avoidance (range 0 - 21), and obsessive/compulsive behavior (range 0 - 9). The total score is the sum of all items (range 0 - 87). Items are rated on a scale of "not a problem" (0) to "severe problem" (3).
Measured: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): Social Avoidance subscale
The Anxiety, Depression, and Mood Scale (ADAMS) is a 28-item parent-report scale designed for individuals with disabilities to measure domains of anxiety (range 0 - 21), depression (range 0 - 21), hyperactivity (range 0 - 15), social avoidance (range 0 - 21), and obsessive/compulsive behavior (range 0 - 9). The total score is the sum of all items (range 0 - 87). Items are rated on a scale of "not a problem" (0) to "severe problem" (3).
Measured: Baseline to Week 12
Social Responsiveness Scale - 2nd Edition (SRS-2): total T-score
The Social Responsiveness Scale - 2nd Edition (SRS-2) is a standardized questionnaire that provides T-scores in domains of social communication, social motivation, social cognition, and restrictive/repetitive behaviors. The SRS-2 Total T-score ranges from 30 to ≥90 with higher scores indicating greater deficiencies in reciprocal social behavior.
Measured: Baseline to Week 12
Ohio Autism Clinical Impressions Scale - Severity (OACIS-S) scale
The Ohio Autism Clinical Impressions Scale - Severity (OACIS-S) is a 10-item, clinician completed measures based upon interview and/or observation. The OACIS-S assesses severity in domains of social interaction, aberrant behavior (including irritability and aggressive behavior), repetitive or ritualistic behavior, verbal communication, nonverbal communication skills, hyperactivity and inattention, anxiety and fearfulness, sensory sensitivities, restricted and narrow interests, and a global rating of autism severity. A 7-point Likert scale is used with scores ranging from "normal" (1) to "among the most severe" (7).
Measured: Baseline to Week 12
Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) scale
The Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) is a 10-item, clinician completed measures based upon interview and/or observation. The OACIS-I assesses improvement in domains of social interaction, aberrant behavior (including irritability and aggressive behavior), repetitive or ritualistic behavior, verbal communication, nonverbal communication skills, hyperactivity and inattention, anxiety and fearfulness, sensory sensitivities, restricted and narrow interests, and a global rating of autism severity. A 7-point Likert scale is used with scores ranging from "very much improved" (1) to "very much worse" (7).
Measured: Baseline to Week 12
Autism Screening Instrument for Educational Planning - 3rd Edition (ASIEP - 3): Interaction Assessment Autism Interaction Score
The Autism Screening Instrument for Educational Planning - 3rd Edition (ASIEP-3) is a 12-minute play-based assessment that evaluates social interactions and social responses. Videos of the session are coded for interactions, social avoidance, and negative behaviors (self-stimulatory, aggression). The vocal behavior is also coded as a separate domain to provide a sample of language function.
Measured: Baseline to Week 12
Repetitive Behavior Scale - Revised (RBS-R)
The Repetitive Behavior Scale - Revised (RBS-R) is a caregiver-completed, 43-item questionnaire assessing repetitive behaviors with 6 subscales: stereotyped (range 0 - 27), ritualistic/sameness (range 0 - 36) , self-injurious (range 0 - 24), compulsive (range 0 - 18), and restricted (range 0 - 9). The total score ranges from 0 to 129, with a higher score indicating more significant problems with repetitive behaviors. Repetitive Behaviors are assessed using a 4-point Likert scale. Scores range from "behavior does not occur" (0) to "behavior occurs and is a severe problem" (3).
Measured: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Global Executive Functioning Score
The Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2) is a standardized rating scale that measures domains of executive functioning, including behavior regulation (inhibition, self-monitoring), emotional regulation (shifting, emotional control), and cognitive regulation (initiation, working memory, plan/organize, task monitoring, and organization of materials). It is made up of 63 items with three answer options (1 = Never; 2= Sometimes; 3=Often). Each item on the parent form is scored 1-3 (1 = Never; 2 = Sometimes; 3 = Often), yielding a raw score of the global scale range from 63 to 189. T scores (M = 50, SD = 10) are used to interpret the level of executive functioning. T-score range is 0-100, and higher scores are indicative of more severe deficiency - 65 or higher is considered to be in the "clinically significant" range.
Measured: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): ADHD score
The Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2) is a standardized rating scale that measures domains of executive functioning, including behavior regulation (inhibition, self-monitoring), emotional regulation (shifting, emotional control), and cognitive regulation (initiation, working memory, plan/organize, task monitoring, and organization of materials). It is made up of 63 items with three answer options (1 = Never; 2= Sometimes; 3=Often). For the ADHD score, 18 items on the BRIEF-2 that correlate with clinical criteria for a diagnosis of ADHD each receive a score from 1-3 (1 = Never; 2 = Sometimes; 3 = Often). These items are summed and produce a range from 18-54, with higher values indicating more ADHD symptoms.
Measured: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Index scores
The Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2) is a standardized rating scale that measures domains of executive functioning, including 3 index scores of behavior regulation (inhibition, self-monitoring), emotional regulation (shifting, emotional control), and cognitive regulation (initiation, working memory, plan/organize, task monitoring, and organization of materials). It is made up of 63 items with three answer options (1 = Never; 2= Sometimes; 3=Often). Each item on the parent form is scored 1-3 (1 = Never; 2 = Sometimes; 3 = Often), yielding a raw score of the global scale range from 63 to 189. T scores (M = 50, SD = 10) are used to interpret the level of executive functioning. T-score range is 0-100, and higher scores are indicative of more severe deficiency - 65 or higher is considered to be in the "clinically significant" range.
Measured: Baseline to Week 12
Sleep Clinical Global Impressions - Severity Scale (Sleep CGI-S)
The Sleep Clinical Global Impressions - Severity Scale (Sleep CGI-S) is a clinician completed measure based upon interview which assesses severity in domains of ability to fall asleep and remain sleeping independently, bedtime resistance; sleep onset delay; night awakening; caregiver satisfaction with their child's current sleep patterns; family functioning, as affected by their child's current sleep patterns. A 7-point Likert scale is used for each domain with scores ranging from "no concerns"/"does not occur" (1) to "Among the worst" (7).
Measured: Baseline to Week 12
Sleep Clinical Global Impressions - Improvement Scale (Sleep CGI-I)
The Sleep Clinical Global Impressions - Improvement Scale (Sleep CGI-I) is a clinician completed measure based upon interview which assesses improvement in domains of ability to fall asleep and remain sleeping independently, bedtime resistance; sleep onset delay; night awakening; caregiver satisfaction with their child's current sleep patterns; family functioning, as affected by their child's current sleep patterns. A 7-point Likert scale is used for each domain with scores ranging from "very much improved" (1) to "very much worse" (7).
Measured: Baseline to Week 12
Autism Family Experience Questionnaire (AFEQ)
The Autism Family Experience Questionnaire (AFEQ) is a 48-item questionnaire that measures family quality of life with domains of experience of being a parent (range 13 - 65), family live (range 9 - 45), child development and social relationships (range 14 - 70), and child's feelings and behavior (range 12 - 60). The sum of all domains gives the total score (range 48 - 240). Each question is assessed using a 5-point Likert scale. Scores range from "always" (1) to "never" (5)". For the total score and the domain scores a higher score indicates a lower outcome.
Measured: Baseline to Week 12
NIH Toolbox Scales: Satisfaction with Social Roles and Activities - Short Form 4a
National Institutes of Health Patient Reported Outcome Measures Information System (NIH PROMIS) will be used to quantify psychological wellbeing and quality of life through self-report and/or parent proxy report. Satisfaction with Social Roles and Activities - Short Form 4a assesses satisfaction with performing one's usual social roles and activities and uses a 5-point Likert scale with scores ranging from "not at all" (1) to "very much" (5). The sum of all scores yields a total raw score (range 4 - 20) with higher scores indicating a greater level of satisfaction. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10.
Measured: Baseline to Week 12
NIH Toolbox Scales: Life Satisfaction - Short Form 8b
National Institutes of Health Patient Reported Outcome Measures Information System (NIH PROMIS) will be used to quantify psychological wellbeing and quality of life through self-report and/or parent proxy report. Life Satisfaction - Short Form 8b assesses an individual's cognitive evaluation of life experiences and whether one likes his/her life or not. Each question is scored using a 5-point Likert scale with scores ranging from "not at all" (1) to "very much" (5). The sum of all scores yields a total raw score (range 8 - 40) with higher scores indicating a greater level of satisfaction. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10.
Measured: Baseline to Week 12
NIH Toolbox Scales: Positive Affect - Short Form 4a
National Institutes of Health Patient Reported Outcome Measures Information System (NIH PROMIS) will be used to quantify psychological wellbeing and quality of life through self-report and/or parent proxy report. Positive Affect - Short Form 41 assesses momentary positive or rewarding affective experiences, such as feelings and mood associated with pleasure, joy, happiness, and excitement. Each question is scored using a 5-point Likert scale with scores ranging from "not at all" (1) to "very much" (5). The sum of all scores yields a total raw score (range 4 - 20) with higher scores indicating a greater level of positive affect. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10.
Measured: Baseline to Week 12
Pediatric Quality of Life Inventory (PedsQL) - Core Scale
The Pediatric Quality of Life Inventory (PedsQL) - Core Scale is a 23-item caregiver questionnaire to evaluate overall quality of life (QOL) in domains of physical functioning, emotional functioning, social functioning, and school functioning. A 5-point Likert scale is used with responses ranging from "Never" (0) to "Almost Always" (4). Items are reversed scored and transformed to a 0 - 100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. The total score is the sum of all the items over the number of items answered with higher scores indicating better health-related quality of life (HRQoL).
Measured: Baseline to Week 12
Pediatric Quality of Life Inventory (PedsQL) - Cognitive Functioning Scale
The Pediatric Quality of Life Inventory (PedsQL) - Cognitive Scale is a 6-item caregiver questionnaire to evaluate an individual's mental abilities including learning, thinking, remembering and attention . A 5-point Likert scale is used with responses ranging from "Never" (0) to "Almost Always" (4). Items are reversed scored and transformed to a 0 - 100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. The total score is the sum of all the items over the number of items answered with higher scores indicating lower problems.
Measured: Baseline to Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2020
- Study start15 Dec 2021
- Primary completion31 Jan 2024
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- For this study, participants will be randomly assigned to one of the following groups: 1. Group A will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks. 2. Group B will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks 3. Group C will receive cannabidiol throughout the entire 27 weeks of treatment
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 86 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04520685
- Sponsor's protocol ID
- 19-2168
- Acronym
- CASCADE
- Status last verified
- May 2024
- First submitted
- 29 Jul 2020
- Last updated
- 8 May 2024
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Sannar EM, Winter J, Franke RK, Werner E, Rochowiak R, Romani PW, Miller OS, Semmler N, Bainbridge JL, Natvig C, Mikulich-Gilbertson SK, Tartaglia NR. Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. Int J Clin Trials. 2025 Jan-Mar;12(1):29-37. doi: 10.18203/2349-3259.ijct20250131. Epub 2025 Jan 28.
PubMed 41103807Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
PubMed 37811711
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CAnnabidiol Study in Children With Autism Spectrum DisordEr (CASCADE): A Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Cannabidiol in Children and Adolescents With Autism
- ClinicalTrials.gov ID
- NCT04520685
- Acronym / sponsor ID
- CASCADE / 19-2168
- Conditions
- Autism Spectrum Disorder
- Keywords
- CBD, cannabidiol, ASD, autism spectrum disorder, autism
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 86 participants (actual)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Study start
- 15 Dec 2021 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 20 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.
Detailed description
Autism spectrum disorder (ASD) is a relatively common neurodevelopmental disorder manifest by social communication deficits and restricted and repetitive interests. Individuals with ASD often have behavioral issues and psychiatric comorbidities which can be very hard to manage. Currently, there are only two FDA approved medications (aripiprazole and risperidone) for the treatment of irritability in ASD. Both medications have the potential for side effects and are not tolerated in all children with ASD. Anecdotal and some preliminary studies suggest that cannabidiol (CBD), a non-psychoactive cannabinoid in the marijuana plant, may lead to improvements in symptoms of ASD including irritability, aggressive behaviors, and anxiety.
In this study the investigators will test whether CBD leads to differences in behaviors commonly associated with ASD. The main behavioral problems investigators will study are irritability and aggressive behavior. This study will also measure changes in other behaviors seen in ASD such as anxiety, social interaction difficulties, repetitive behaviors, attentional problems, hyperactivity, repetitive behaviors, and quality of life. Study investigators will also test whether there are any important side effects of CBD in children and adolescents with ASD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
- Model description
- For this study, participants will be randomly assigned to one of the following groups: 1. Group A will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks. 2. Group B will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks 3. Group C will receive cannabidiol throughout the entire 27 weeks of treatment
| Arm | Type | Receives |
|---|---|---|
| Arm 1: 12 weeks of study drug then 15 weeks of placebo | Experimental | Drug: Oral cannabidiol 100mg/mL, Drug: PlaceboSubjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks. |
| Arm 3: 15 weeks of placebo then 12 weeks of study drug | Experimental | Drug: Oral cannabidiol 100mg/mL, Drug: PlaceboSubjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks. |
| Arm 3: 27 weeks of study drug | Experimental | Drug: Oral cannabidiol 100mg/mLSubjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment. |
Who may qualify
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (15 listed)
- Male or female children and adolescents aged 5-17 years, inclusive, at the time of screening.
- Judged by the investigator to be in good health at screening based upon the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results.
- Patients must have a previous documented diagnosis of ASD by a medical or psychological professional.
- Patients must be assessed by the Investigator as being moderately to severely impacted due to ASD
- Patients who are taking psychotropic medication(s) should be on a stable regimen of no more than 2 medications for at least 4 weeks preceding study Screening and must maintain that regimen throughout the study. Psychotropic medications include (but are not limited to) antipsychotics, antidepressants, mood stabilizers, anxiolytics, and ADHD medications.
Key exclusion criteria (11 listed)
- Adolescent females who are pregnant, nursing, or planning a pregnancy. Females of childbearing potential and male patients with a partner of childbearing potential who are unwilling or unable to use standard acceptable methods of contraception (including abstinence, hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, or intrauterine device) for the duration of the study and for 1 month after the last dose of study medication.
- History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to CBD (Epidiolex) or its ingredients.
- Exposure to any investigational drug or device < 30 days prior to screening, or plans to take another investigational drug at any time during the study.
- Use of any THC or CBD-containing product within 4 weeks of Screening Visit, planned use during the study, or positive THC urine test at screening.
- Patient is using the following medications: clobazam (Onfi, Frisium), felbamate (Felbatol), vigabatrin (Sabril), or everolimus (Afinitor).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral cannabidiol 100mg/mLIn Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day. | Drug | Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug, Arm 3: 27 weeks of study drug |
| PlaceboIn Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day. | Drug | Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug |
Primary outcome
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score
Time frame: Baseline to Week 12
The Aberrant Behavior Checklist- 2nd Edition (ABC-2) is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials. The ABC-2 is a 58-item questionnaire and measures domains of Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/noncompliance, and Inappropriate Speech. Behaviors are assessed using a 4-point Likert scale. Scores range from "not at all a problem" (0) to "the problem is severe in degree" (3). The Irritability subscale range is from 0 to 45.
23 secondary outcomes
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Lethargy/Social Withdrawal subscale
Time frame: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Stereotypic Behavior subscale
Time frame: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Inappropriate Speech subscale
Time frame: Baseline to Week 12
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Hyperactivity/Noncompliance subscale
Time frame: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): Total Score
Time frame: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): General Anxiety subscale
Time frame: Baseline to Week 12
Anxiety, Depression, and Mood Scale (ADAMS): Social Avoidance subscale
Time frame: Baseline to Week 12
Social Responsiveness Scale - 2nd Edition (SRS-2): total T-score
Time frame: Baseline to Week 12
Ohio Autism Clinical Impressions Scale - Severity (OACIS-S) scale
Time frame: Baseline to Week 12
Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) scale
Time frame: Baseline to Week 12
Autism Screening Instrument for Educational Planning - 3rd Edition (ASIEP - 3): Interaction Assessment Autism Interaction Score
Time frame: Baseline to Week 12
Repetitive Behavior Scale - Revised (RBS-R)
Time frame: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Global Executive Functioning Score
Time frame: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): ADHD score
Time frame: Baseline to Week 12
Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Index scores
Time frame: Baseline to Week 12
Sleep Clinical Global Impressions - Severity Scale (Sleep CGI-S)
Time frame: Baseline to Week 12
Sleep Clinical Global Impressions - Improvement Scale (Sleep CGI-I)
Time frame: Baseline to Week 12
Autism Family Experience Questionnaire (AFEQ)
Time frame: Baseline to Week 12
NIH Toolbox Scales: Satisfaction with Social Roles and Activities - Short Form 4a
Time frame: Baseline to Week 12
NIH Toolbox Scales: Life Satisfaction - Short Form 8b
Time frame: Baseline to Week 12
NIH Toolbox Scales: Positive Affect - Short Form 4a
Time frame: Baseline to Week 12
Pediatric Quality of Life Inventory (PedsQL) - Core Scale
Time frame: Baseline to Week 12
Pediatric Quality of Life Inventory (PedsQL) - Cognitive Functioning Scale
Time frame: Baseline to Week 12
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2024.
- Derived from this study: PubMed 41103807Sannar EM, Winter J, Franke RK, Werner E, Rochowiak R, Romani PW, Miller OS, Semmler N, Bainbridge JL, Natvig C, Mikulich-Gilbertson SK, Tartaglia NR. Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. Int J Clin Trials. 2025 Jan-Mar;12(1):29-37. doi: 10.18203/2349-3259.ijct20250131. Epub 2025 Jan 28.
- Derived from this study: PubMed 37811711Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
Related trials for Autism Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Recruiting
Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism
Autism, Autism Spectrum Disorder
Recruiting
Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism
Autism Spectrum Disorder, Autism
RecruitingPhase 2
A Study of Esomeprazole in Children With Autism
Autism, Autism Spectrum Disorder
Recruiting
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Autism Spectrum Disorder, Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Oral cannabidiol 100mg/mL in people with Autism Spectrum Disorder, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score (time frame: Baseline to Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04520685, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2024.